Ames, United States
NewLink Genetics, now operating under the name Lumos Pharma, Inc., is a distinguished player in the biopharmaceutical industry. Founded in 1999, the company is headquartered in the United States. It focuses on the discovery, development, and commercialization of novel immuno-oncology products to transform cancer treatment.
Over its extensive operational period, NewLink Genetics has effectively positioned itself at the cutting-edge of cancer treatment innovation. The company's robust R&D efforts are fueled by a team comprising seasoned industry professionals and physician-scientists committed to altering the oncology landscape. The passion driving their work is derived from compelling personal cancer experiences.
The company's last recorded investment was a $7.50 million Series D investment on July 21, 2009. Although the specific investors were not disclosed, this financial backing highlights investor confidence in NewLink Genetics’ innovative approach and growth potential.
ALX Oncology
Apexigen